CompoAtlas

Herbesan Sommeil Serein

Food supplement declared in France, decision dated 29 July 2026

Herbesan Sommeil Serein, from LABORATOIRES SUPER DIET, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Valeriana officinalis 586 mg per day, Passiflora incarnata 390 mg per day, Crataegus monogyna 130 mg per day, Eschscholzia californica 60 mg per day, Humulus lupulus 60 mg per day. 1 rule of use applies to its ingredients (limits and warnings).

Brand
Herbesan
Food business operator placing the product on the market
LABORATOIRES SUPER DIET
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Sleep

Declaration 371708, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Valeriana officinalis L.RacineExtrait sec hydroalcoolique586 mg
Passiflora incarnata L.Sommités fleuriesExtrait sec hydroalcoolique390 mg
Crataegus monogyna Jacq.Sommités fleuriesPoudre (de plantes séchées ou broyées)130 mg
Eschscholzia californica Cham.Parties aériennesPoudre (de plantes séchées ou broyées)60 mg
Humulus lupulus L.CônePoudre (de plantes séchées ou broyées)60 mg
Melissa officinalis L.FeuillePoudre (de plantes séchées ou broyées)60 mg
Passiflora incarnata L.Parties aériennesPoudre (de plantes séchées ou broyées)38 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
magnesium oxideMagnesium250 mg300 mg

Additives

E553b, E470b

Other ingredients

maltodextrine, Gélatine de poisson

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Valeriana officinalis L.
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    Sources cited by Health Canada (3)
    • Barnes J, Anderson LA, Phillipson JD. Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press; 2002.
    • Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K, Brinckmann J, Wollschlaeger B, editors. 2003. The ABC Clinical Guide to Herbs: Valerian. Austin, Texas: American Botanical Council.
    • Mills E, Dugoua J, Perri D, Koren G. 2006. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (GB): Taylor and Francis Medical.

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    Sources cited by Health Canada (2)
    • Gennaro AR, Marderosian AHD, Hanson GR, Medwick T, editors. 2000. Remington: The Science and Practice of Pharmacy, 20th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications. 2010.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 1992. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2002. Pharmacotherapy: A Pathophysiologic Approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.
    • EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

  • Passiflora incarnata L.
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Health Canada monograph dated 29 November 2024

  • Crataegus monogyna Jacq.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • Eschscholzia californica Cham.
    Read the warning, when it applies and the studies cited

    CALIFORNIA POPPY - ESCHSCHOLZIA CALIFORNICA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.

    Condition of application: Other uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    When using this product avoid taking with alcohol or products that cause drowsiness and/or with analgesic properties (Brinker 2010; Mills and Bone 2005; Hoffmann 2003).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2015; Berardi et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • EMA 2015: European Medicines Agency. European Union herbal monograph on Eschscholzia californica Cham., herba London. (UK): Committee on Herbal Medicinal Products (HMPC); 2015. [Accessed 2024 March 1]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf.

    Contraindications

    Do not use if you are pregnant (Brinker 2010; Blumenthal et al. 2000).

    Sources cited by Health Canada (2)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Health Canada monograph dated 28 February 2025

  • Humulus lupulus L.
    Read the warning, when it applies and the studies cited

    HOPS - HUMULUS LUPULUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.

    Condition of application: Other uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).

    Sources cited by Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014 : European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 6 Mai 2014. [Consulté le 14 septembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf

    When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).

    Sources cited by Health Canada (5)
    • EMA 2014: European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 6 May 2014. [Accessed 2023 September 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3e édition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    Health Canada monograph dated 26 April 2024

  • Melissa officinalis L.
    Read the warning, when it applies and the studies cited

    LEMON BALM -MELISSA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 April 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : Herbesan

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Herbesan Sommeil Serein: composition and regulation”, https://compoatlas.com/en/supplements/products/371708-herbesan-sommeil-serein, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line